SecBot SecBot
SECBOTREPLAY Home › Report › PROK

PROK · Q3 cash $142M, trial on track

PROKIDNEY CORP. · 8-K filed Nov 9, 2026 at 07:00 ET

At the news

NEUTRALIMPACT 3/10

8-K filed Nov 9, 2026 at 07:00 ET

ProKidney reported Q3 2026 cash and marketable securities of $141.9 million, down from $181.6 million at Q2 2026, and updated its investor presentation with Phase 3 PROACT 1 milestones: full enrollment expected Q1 2027, topline eGFR slope data in Q2 2027, and BLA submission in Q1 2028. The company has no revenue and continues to burn cash to fund its clinical trials, with cash runway into mid-2027. The filing is routine for a pre-revenue biotech and does not contain a material change in financial condition or clinical outlook.

  • Cash, cash equivalents and marketable securities as of September 30, 2026 was $141.9 million, compared to $181.6 million at June 30, 2026.
  • Phase 3 PROACT 1 study full enrollment expected Q1 2027 (over 500 patients, up from 470).
  • Topline eGFR slope data for accelerated approval anticipated Q2 2027.
  • BLA submission for accelerated approval expected Q1 2028.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access